J.A. Levi
Impact in
- Genetics top 10%
- Glioma Diagnosis and Treatment
-
- Brain Metastases and Treatment
- Lung Cancer Treatments and Mutations
Papers in
- Co-authors
- David Bell (5 shared papers)R. Woods (1 shared paper)R. N. HITCHINS (1 shared paper)Derek Raghavan (4 shared papers)VJ Harvey (2 shared papers)D. Dalley (2 shared papers)Wing‐Kai Chan (1 shared paper)R. S. Aroney (1 shared paper)
- Journals
- Journal of Clinical Oncology (2 papers)European Journal of Cancer (1 paper)Thorax (1 paper)The Lancet (1 paper)Gynecologic Oncology (1 paper)
- Partner nations
- AustraliaBelgiumNew Zealand
In The Last Decade
J.A. Levi
13 papers receiving 638 citations
Peers
Comparison fields: 5 of 49
- Genetics 138
- Pulmonary and Respiratory Medicine 369
- Oncology 215
- Surgery 254
- Neurology 74
Countries citing papers authored by J.A. Levi
This map shows the geographic impact of J.A. Levi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.A. Levi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.A. Levi more than expected).
Fields of papers citing papers by J.A. Levi
This network shows the impact of papers produced by J.A. Levi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.A. Levi. The network helps show where J.A. Levi may publish in the future.
Co-authors
The 25 scholars most cited alongside J.A. Levi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 1987 | 272 | |
| 2 | 1993 | 102 | |
| 3 | 2001 | 76 | |
| 4 | 1981 | 68 | |
| 5 | 1988 | 65 | |
| 6 | 1996 | 42 | |
| 7 | A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand. | 1997 | 9 |
| 8 | 1983 | 7 | |
| 9 | 1989 | 7 | |
| 10 | Ifosfamide combination regimens for soft-tissue sarcoma. | 1993 | 6 |
| 11 | 1988 | 5 | |
| 12 | 1985 | 4 | |
| 13 | 2009 | 2 |
About J.A. Levi
J.A. Levi is a scholar working on Surgery, Oncology, Pulmonary and Respiratory Medicine, Epidemiology and Reproductive Medicine, having authored 13 papers that have together received 665 indexed citations. Recurring topics across this work include Lung Cancer Research Studies (4 papers), Testicular diseases and treatments (4 papers), Sarcoma Diagnosis and Treatment (2 papers), Neuroendocrine Tumor Research Advances (2 papers), Brain Metastases and Treatment (2 papers), Ovarian cancer diagnosis and treatment (2 papers), Metastasis and carcinoma case studies (1 paper) and Urologic and reproductive health conditions (1 paper). The work is most often cited by research in Genetics (138 citations), Pulmonary and Respiratory Medicine (369 citations), Oncology (215 citations), Surgery (254 citations) and Neurology (74 citations). J.A. Levi has collaborated with scholars based in Australia, Belgium and New Zealand. Frequent co-authors include David Bell, R. Woods, R. N. HITCHINS, Derek Raghavan, VJ Harvey, D. Dalley, Wing‐Kai Chan, R. S. Aroney, Robert L. Woods and Z. Kerestes. Their work appears in journals such as Journal of Clinical Oncology, European Journal of Cancer, Thorax, The Lancet and Gynecologic Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.